Form 4: Avidity Biosciences CEO Sarah Boyce Executes Stock Options and Sells Shares Under 10b5-1 Plan

Avidity Biosciences' CEO, Sarah Boyce, exercised stock options and sold shares of common stock between June 12 and June 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Sarah Boyce, the President and CEO of Avidity Biosciences, executed stock options and sold shares of the company's common stock.
• These transactions occurred between June 12 and June 14, 2024.
• The exercises and sales were conducted under a Rule 10b5-1 trading plan adopted on June 9, 2023.
• On June 12, 2024, Boyce exercised options for 100,000 shares at a price of $1.24 and sold the same amount at a weighted-average price of $35.7302.
• On June 13, 2024, she exercised options for 164,233 shares at $1.24 and sold them at a weighted-average price of $40.076.
• On June 14, 2024, Boyce exercised options for 35,767 shares at $1.24 and sold them at a weighted-average price of $40.0784.
• Following these transactions, Boyce directly owns 112,117 shares of common stock and holds options for 517,015 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned strategy, suggesting no immediate cause for alarm or excessive optimism. The CEO is realizing some gains, which is normal.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan can alleviate these concerns.

Industry Context

Executive stock transactions are common in publicly traded companies, and the use of Rule 10b5-1 plans is a standard practice to allow insiders to sell shares while avoiding accusations of insider trading. These plans are often viewed as a way for executives to diversify their holdings or manage personal finances.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a significant component.
• The exercise and sale of these options are typical events.
• Rule 10b5-1 trading plans are widely used by executives at companies like Amgen, Biogen, and Gilead Sciences to manage their stock sales in a compliant manner.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, depending on how they interpret the executive's stock sales.
• The use of a 10b5-1 plan should reassure stakeholders that the sales were pre-planned and not based on inside information.

Key Dates